Actym Therapeutics, which focuses on the discovery and development of novel therapies intended for the treatment of cancer, and Wacker Biotech agreed on a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors.
Under the terms of the agreement, Wacker Biotech will begin GMP production of Phase I clinical material of Actym’s therapeutic candidate at its site in Amsterdam using its LIBATEC® technology. Both companies have already been working on technology transfer and initiation of scale-up production of ACTM-838, which is Actym’s lead clinical development candidate for solid tumor therapy.
The therapeutic candidate is based on the company’s immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy), which delivers active compounds directly to tumor-resident immune cells.
“Manufacturing of ACTM-83 is an important milestone for our company. We are excited to work with Wacker Biotech given their significant experience manufacturing GMP-compliant, live microbial products in a closed production system,” said Christopher Thanos, PhD, Actym’s president and CEO. “Wacker Biotech’s expertise in large-scale, high-quality microbial manufacturing is a perfect fit for production of therapeutic candidates for clinical testing from Actym’s state-of-the-art STACT platform.”
Wacker Biotech, a CDMO that will use its LIBATEC® technology platform for live microbial products (LMPs) in the project. “Our LIBATEC platform can be used for a wide range of LMPs,” added Jörg Lindemann, managing director of Wacker Biotech. “It is perfectly suited to supporting Actym with their STACT platform.”
Besides GMP-compliant process development and manufacturing, LIBATEC will be used for the development of analytical methods.